Pfizer Inc. (PFE) Q1 2026 (USD): adj. EPS 0.75 (exp. 0.72), Revenue 14.5bln (exp. 13.84bln). Reaffirms Guidance: Current FY EPS 2.80-3.00 (exp. 2.96), Current FY Rev. 59.5-62.5bln (exp. 61.38bln)
- Vyndamax Patent Settlements: Prev. exp. a "significant decline" in US revenue for Vyndamax from 2029, however, the settlement means revenue is seen as stable through mid-2031.
- CEO "Off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts ... particularly encouraged by what we're seeing in oncology and obesity, two areas where I believe Pfizer is positioned to lead.”
Context
Pfizer's Q1 results show a solid beat on both adjusted EPS and revenue, reinforcing confidence in their guidance for the fiscal year. The patent settlements for Vyndamax stabilize revenue projections, providing a favorable outlook amid ongoing advancements in their R&D pipeline, particularly in key therapeutic areas. This may bolster sentiment in pharmaceuticals and related sectors, potentially impacting broader market indices.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#PFIZER INC#PFE.US#IMPORTANT#FOREX#EQUITIES#METALS#EU SESSION#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#DXY#US EQUITIES